|
Characteristic
|
Ezetimibe add- on group (n = 23)
|
Increased rosuvastatin (n = 20)
|
|---|
|
Age, years†
|
56.5 ± 7.4
|
57.0 ± 9.9
|
|
Male sex
|
22 (95.6)
|
17 (85.0)
|
|
Caucasian
|
19 (82.6)
|
15 (75.0)
|
|
Duration of ARV therapy (months)†
|
24 (16–34)
|
25(14-48)
|
|
CD4+ cell count (cells/mm3)†
|
580.0 ± 193
|
508.0 ± 208
|
|
Undetectable VL‡
|
20 (87.0)
|
19 (95.0)
|
|
PI
|
21 (91.3)
|
17 (85.0)
|
|
NNRTI
|
6 (26.1)
|
7 (35.0)
|
|
NRTI
|
23 (100)
|
19 (95.0)
|
|
Fibrate
|
4 (17.4)
|
6 (30.0)
|
|
Antihypertensive agents
|
13 (56.5)
|
6 (30.0)
|
|
Current Smoker
|
6 (26.1)
|
1 (5.0)
|
|
Previous Smoker§
|
8 (34.8)
|
14 (70.0)
|
|
Diabetes Mellitus
|
8 (34.8)
|
7 (35.0)
|
|
Hypertension
|
13 (56.5)
|
6 (30.0)
|
|
Family History of CVD
|
10 (43.5)
|
10 (55.0)
|
|
Body Mass Index (kg/m2)†
|
26.0 ± 4.2
|
25.3 ± 4.7
|
|
Waist Circumference, cm†
|
98 ± 13.7
|
93 ± 15.3
|
- *Data are frequency (%) unless otherwise indicated
- †Data are mean (±SD)
- ‡ < 40 copies/mL
- § less than one year of smoking cessation prior to study recruitment
- ARV, antiretroviral; VL, viral load; PI, protease inhibitor; NNRTI, non-nucleoside
- reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase; CVD, cardiovascular disease
